Biointron’s 2026 Antibody Industry Outlook aims to explore the events and trends of the biopharmaceutical industry for 2026. Last year, 21 novel monoclonal antibody drugs have been approved by China, United States, Europe, and Australia.
Recent work in antibody-cytokine fusion proteins reflects a clear engineering objective: retain the immunostimulatory capacity of cytokines while reducing systemic toxicities associated with non-restricted receptor engagement.
Radioligand therapy (RLT), also known as radiopharmaceutical therapy, is quickly becoming a major player in the oncology therapeutics space, specifically radioantibodies.
Time: June 17-18, 2026
Location: Cambridge, MA
Time: December 13 - 16, 2026
Location: San Diego, CA
Time: November 17 – 19, 2026
Location: Lisbon Congress Center | Lisbon, Portugal
Booth: #320
Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.
WhenThursday, October 16, 2025 · 11:00 a.m.Eastern Time (US & Canada) (GMT -4:00)Register here >>AboutSuccessful antibody discovery requires more than just access to powerful platforms - it demands the experience to apply them efficiently and strategically.In this webinar, we
Biointron’s Lunch & Learn with KACTUS was held at CIC Cambridge, MA on September 12. The session featured three key speakers: Sagar Kathuria, PhD (Senior Principal Scientist at Sanofi), Alexander Hostetler, PhD (Application Scientist at KACTUS Biosystems), and Gang Liu, PhD (Director of Discovery Services at Biointron). We thoroughly enjoyed hosting the event and the audience’s strong engagement!
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Join Biointron’s Google Review & Reward Program! Share your experience on Biointron google profile and earn a $25 gift card as reward!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This month in January, we'll do a deep dive into last year's novel antibody drugs, G protein-coupled receptors, and fusion proteins.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This December, we'll highlight the antibody startup ecosystem, microfluidic strategies driving next-generation antibody discovery, and the landscape of psoriasis treatment.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This November, we'll highlight how non-canonical antibodies are reshaping immunotherapy, combination antibody therapies, and T cell exhaustion.
January 2026 deal activity leaned heavily toward bispecific, trispecific, and ADC assets, particularly in oncology and immunology, alongside steady investment in AI-enabled target discovery and antibody engineering platforms. Several of the month’s largest transactions focused on late preclinical and early clinical programs, pointing to continued pharma interest in differentiated antibody modalities with well-defined mechanisms as the year gets underway.
This article examines HEK293 and CHO across biological characteristics, productivity, glycosylation, product integrity, and application-specific strategy, integrating findings from recent comparative studies.
ADCs to watch in 2026. Clinical Trials, Primary Endpoints.
You can also contact us on the Scientist and Science Exchange marketplaces.
